Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey

Chen, Hong1; Zhang, Yuming2; Jiang, Yirong3; Lin, LiE4; Cheng, Shuqin5; Xu, Xiaojun6; Zhang, Xiong7; Lin, Haiqing8; Huang, Zhenqian9; Wang, Qiang1; Zhou, Xuan1; Qu, Hong5; Liu, Xiaoli1,11; Li, Weiming10,12; Xu, Na1,11

2023-07-03

10.1080/10428194.2023.2217711

LEUKEMIA & LYMPHOMA   Impact Factor & Quartile

1042-8194

1029-2403

The experience of a physician at a clinical center is among the critical factors in managing chronic myeloid leukemia (CML) during its treatment with tyrosine kinase inhibitors (TKIs). The authors conducted a cross-sectional questionnaire to investigate barriers to physician use of published evidence-based guidelines in CML management in a real-world setting. Among the participating physicians (N = 407), 99.8% of physicians reported that CML guidelines were useful; however, only 62.9% of physicians reported that they follow guidelines in real-time. Although 90.7% of physicians prefer second-generation TKIs as the first-line treatment, imatinib (88.2%) remains the most widely administered TKI in the first-line setting. Only 50.6% of physicians switched the treatment when patients failed to achieve early molecular response (at 3 months), whereas 70.3% of physicians switched the treatment when patients' response to TKI was inadequate at 6 months and/or 12 months. Moreover, only 43.5% of physicians considered treatment-free remission (TFR) as one of the top 3 goals for their patients. The major concern to obtain TFR was patients' adherence. This study demonstrated that CML management was generally in line with the current guidelines, but some of the details at the point of care are needed to be improved in CML.

Chronic myeloid leukemia first-line treatment early switching treatment-free remission

SCI

English

Others

Natural Science Foundation of Guangdong Province, China["2020A1515010409","2022A1515011043"] ; Applied Basic Research Program of Science, China[202201011781]

Oncology ; Hematology

Oncology ; Hematology

WOS:001002958700001

TAYLOR & FRANCIS LTD

Web of Science

1.Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
2.Guangdong Med Univ, Affiliated Hosp, Dept Hematol, Zhanjiang, Peoples R China
3.Southern Med Univ, Affiliated Dongguan Peoples Hosp, Dongguan Peoples Hosp, Dept Hematol, Dongguan, Peoples R China
4.Hainan Gen Hosp, Dept Hematol, Haikou, Peoples R China
5.Panyu Cent Hosp, Dept Hematol, Guangzhou, Peoples R China
6.Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hematol, Shenzhen, Peoples R China
7.Maoming Peoples Hosp, Dept Hematol, Maoming, Peoples R China
8.Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Dept Hematol,Clin Med Coll 2,Affiliated Hosp 1, Shenzhen, Peoples R China
9.Guangzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China
10.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China
11.Southern Med Univ, Nanfang Hosp, Dept hematol, Guangzhou 510515, Peoples R China
12.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan 430022, Peoples R China

Chen, Hong,Zhang, Yuming,Jiang, Yirong,et al. Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey[J]. LEUKEMIA & LYMPHOMA,2023,64(8).

Chen, Hong.,Zhang, Yuming.,Jiang, Yirong.,Lin, LiE.,Cheng, Shuqin.,...&Xu, Na.(2023).Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey.LEUKEMIA & LYMPHOMA,64(8).

Chen, Hong,et al."Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey".LEUKEMIA & LYMPHOMA 64.8(2023).